Literature DB >> 18241213

Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia.

G Perez-Chacon1, S Rosado, N Rebolleda, I Losada-Fernandez, J A Vargas, M Morado, J Jorda, P Perez-Aciego.   

Abstract

In the last few years, it has been suggested that the involvement of human leukocyte antigen-G (HLA-G) in several tumoral processes and its likely participation as a factor of immune tolerance in malignant cells. Recently, positive HLA-G surface expression has been associated with a poor prognosis in a small group of patients with B-cell chronic lymphocytic leukemia (B-CLL), a lymphoproliferative disorder characterized by a heterogeneous clinical course. In the present work, 169 patients suffering from B-CLL were analyzed for the expression of HLA-G by flow cytometry in order to verify its prognostic value in a larger cohort. We observed a low expression of this molecule on leukemic B cells and no significant relation to clinical data or progression-free survival time, indicating that this molecule is not as good immunologic prognostic marker for B-CLL as suggested.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18241213     DOI: 10.1111/j.1751-553X.2008.01030.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  7 in total

1.  Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia.

Authors:  Mónica Villa-Álvarez; Seila Lorenzo-Herrero; Ana P Gonzalez-Rodriguez; Alejandro López-Soto; Angel R Payer; Esther Gonzalez-Garcia; Leticia Huergo-Zapico; Segundo Gonzalez
Journal:  Oncoimmunology       Date:  2017-07-20       Impact factor: 8.110

2.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

3.  Determination of HLA-G Expression and Evaluation of Its Role as a Prognostic Factor in Chronic Lymphocytic Leukemia.

Authors:  Gulsum Ozet; Mesude Falay; Simten Dagdas; Funda Ceran
Journal:  J Clin Lab Anal       Date:  2015-08-24       Impact factor: 2.352

4.  Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.

Authors:  Nerea Rebolleda; Ignacio Losada-Fernandez; Gema Perez-Chacon; Raquel Castejon; Silvia Rosado; Marta Morado; Maria Teresa Vallejo-Cremades; Andrea Martinez; Juan A Vargas-Nuñez; Paloma Perez-Aciego
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 5.  Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?

Authors:  Chilam Chan; Marta Lustig; Niklas Baumann; Thomas Valerius; Geert van Tetering; Jeanette H W Leusen
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

Review 6.  NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

7.  Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma.

Authors:  A Lin; H-X Chen; C-C Zhu; X Zhang; H-H Xu; J-G Zhang; Q Wang; W-J Zhou; W-H Yan
Journal:  J Cell Mol Med       Date:  2010-10-03       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.